215 related articles for article (PubMed ID: 32268604)
1. Extracellular Vesicle Biomarkers Reveal Inhibition of Neuroinflammation by Infliximab in Association with Antidepressant Response in Adults with Bipolar Depression.
Mansur RB; Delgado-Peraza F; Subramaniapillai M; Lee Y; Iacobucci M; Rodrigues N; Rosenblat JD; Brietzke E; Cosgrove VE; Kramer NE; Suppes T; Raison CL; Chawla S; Nogueras-Ortiz C; McIntyre RS; Kapogiannis D
Cells; 2020 Apr; 9(4):. PubMed ID: 32268604
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Adjunctive Infliximab vs Placebo in the Treatment of Adults With Bipolar I/II Depression: A Randomized Clinical Trial.
McIntyre RS; Subramaniapillai M; Lee Y; Pan Z; Carmona NE; Shekotikhina M; Rosenblat JD; Brietzke E; Soczynska JK; Cosgrove VE; Miller S; Fischer EG; Kramer NE; Dunlap K; Suppes T; Mansur RB
JAMA Psychiatry; 2019 Aug; 76(8):783-790. PubMed ID: 31066887
[TBL] [Abstract][Full Text] [Related]
3. Exploring brain insulin resistance in adults with bipolar depression using extracellular vesicles of neuronal origin.
Mansur RB; Delgado-Peraza F; Subramaniapillai M; Lee Y; Iacobucci M; Nasri F; Rodrigues N; Rosenblat JD; Brietzke E; Cosgrove VE; Kramer NE; Suppes T; Raison CL; Fagiolini A; Rasgon N; Chawla S; Nogueras-Ortiz C; Kapogiannis D; McIntyre RS
J Psychiatr Res; 2021 Jan; 133():82-92. PubMed ID: 33316649
[TBL] [Abstract][Full Text] [Related]
4. Peripheral inflammatory biomarkers define biotypes of bipolar depression.
Lee Y; Mansur RB; Brietzke E; Kapogiannis D; Delgado-Peraza F; Boutilier JJ; Chan TCY; Carmona NE; Rosenblat JD; Lee J; Maletic V; Vinberg M; Suppes T; Goldstein BI; Ravindran AV; Taylor VH; Chawla S; Nogueras-Ortiz C; Cosgrove VE; Kramer NE; Ho R; Raison CA; McIntyre RS
Mol Psychiatry; 2021 Jul; 26(7):3395-3406. PubMed ID: 33658605
[TBL] [Abstract][Full Text] [Related]
5. Leptin mediates improvements in cognitive function following treatment with infliximab in adults with bipolar depression.
Mansur RB; Subramaniapillai M; Lee Y; Pan Z; Carmona NE; Shekotikhina M; Iacobucci M; Rodrigues N; Nasri F; Rashidian H; Rosenblat JD; Brietzke E; Cosgrove VE; Kramer NE; Suppes T; McIntyre RS
Psychoneuroendocrinology; 2020 Oct; 120():104779. PubMed ID: 32603956
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of adjunctive infliximab vs. placebo in the treatment of anhedonia in bipolar I/II depression.
Lee Y; Mansur RB; Brietzke E; Carmona NE; Subramaniapillai M; Pan Z; Shekotikhina M; Rosenblat JD; Suppes T; Cosgrove VE; Kramer NE; McIntyre RS
Brain Behav Immun; 2020 Aug; 88():631-639. PubMed ID: 32380271
[TBL] [Abstract][Full Text] [Related]
7. Effects of infliximab on brain neurochemistry of adults with bipolar depression.
Mansur RB; Subramaniapillai M; Lee Y; Pan Z; Carmona NE; Shekotikhina M; Iacobucci M; Rodrigues N; Nasri F; Rosenblat JD; Brietzke E; Cosgrove VE; Kramer NE; Suppes T; Newport J; Hajek T; McIntyre RS
J Affect Disord; 2021 Feb; 281():61-66. PubMed ID: 33296798
[TBL] [Abstract][Full Text] [Related]
8. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers.
Raison CL; Rutherford RE; Woolwine BJ; Shuo C; Schettler P; Drake DF; Haroon E; Miller AH
JAMA Psychiatry; 2013 Jan; 70(1):31-41. PubMed ID: 22945416
[TBL] [Abstract][Full Text] [Related]
9. Glucose and lipid-related biomarkers and the antidepressant response to infliximab in patients with treatment-resistant depression.
Bekhbat M; Chu K; Le NA; Woolwine BJ; Haroon E; Miller AH; Felger JC
Psychoneuroendocrinology; 2018 Dec; 98():222-229. PubMed ID: 30249443
[TBL] [Abstract][Full Text] [Related]
10. Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression.
Park M; Newman LE; Gold PW; Luckenbaugh DA; Yuan P; Machado-Vieira R; Zarate CA
J Psychiatr Res; 2017 Jan; 84():113-118. PubMed ID: 27718369
[TBL] [Abstract][Full Text] [Related]
11. The effect of adjunctive infliximab treatment on future cardiovascular disease risk in patients with bipolar disorder.
Gill H; Rodrigues NB; Mansur RB; Marks CA; DiVincenzo JD; Ceban F; Rosenblat JD; Cao B; Lieberman JM; Ho R; McIntyre RS
J Affect Disord; 2022 Nov; 316():273-279. PubMed ID: 35878838
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional signatures related to glucose and lipid metabolism predict treatment response to the tumor necrosis factor antagonist infliximab in patients with treatment-resistant depression.
Mehta D; Raison CL; Woolwine BJ; Haroon E; Binder EB; Miller AH; Felger JC
Brain Behav Immun; 2013 Jul; 31():205-15. PubMed ID: 23624296
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of infliximab in treatment-resistant depression: A systematic review and meta-analysis.
Bavaresco DV; Uggioni MLR; Ferraz SD; Marques RMM; Simon CS; Dagostin VS; Grande AJ; da Rosa MI
Pharmacol Biochem Behav; 2020 Jan; 188():172838. PubMed ID: 31837338
[TBL] [Abstract][Full Text] [Related]
14. Sertraline ameliorates inflammation in CUMS mice and inhibits TNF-α-induced inflammation in microglia cells.
Lu Y; Xu X; Jiang T; Jin L; Zhao XD; Cheng JH; Jin XJ; Ma J; Piao HN; Piao LX
Int Immunopharmacol; 2019 Feb; 67():119-128. PubMed ID: 30544065
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory cytokines and nuclear factor-kappa B activation in adolescents with bipolar and major depressive disorders.
Miklowitz DJ; Portnoff LC; Armstrong CC; Keenan-Miller D; Breen EC; Muscatell KA; Eisenberger NI; Irwin MR
Psychiatry Res; 2016 Jul; 241():315-22. PubMed ID: 27227701
[TBL] [Abstract][Full Text] [Related]
16. Shank3 as a potential biomarker of antidepressant response to ketamine and its neural correlates in bipolar depression.
Ortiz R; Niciu MJ; Lukkahati N; Saligan LN; Nugent AC; Luckenbaugh DA; Machado-Vieira R; Zarate CA
J Affect Disord; 2015 Feb; 172():307-11. PubMed ID: 25451430
[TBL] [Abstract][Full Text] [Related]
17. Association between childhood trauma exposure and pro-inflammatory cytokines in schizophrenia and bipolar-I disorder.
Quidé Y; Bortolasci CC; Spolding B; Kidnapillai S; Watkeys OJ; Cohen-Woods S; Berk M; Carr VJ; Walder K; Green MJ
Psychol Med; 2019 Dec; 49(16):2736-2744. PubMed ID: 30560764
[TBL] [Abstract][Full Text] [Related]
18. High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study.
Takeuchi T; Miyasaka N; Inui T; Yano T; Yoshinari T; Abe T; Koike T
Arthritis Res Ther; 2017 Sep; 19(1):194. PubMed ID: 28865493
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of antidepressant properties of the p38 MAP kinase inhibitor losmapimod (GW856553) in Major Depressive Disorder: Results from two randomised, placebo-controlled, double-blind, multicentre studies using a Bayesian approach.
Inamdar A; Merlo-Pich E; Gee M; Makumi C; Mistry P; Robertson J; Steinberg E; Zamuner S; Learned S; Alexander R; Ratti E
J Psychopharmacol; 2014 Jun; 28(6):570-81. PubMed ID: 24699061
[TBL] [Abstract][Full Text] [Related]
20. Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trial.
Anand A; Gunn AD; Barkay G; Karne HS; Nurnberger JI; Mathew SJ; Ghosh S
Bipolar Disord; 2012 Feb; 14(1):64-70. PubMed ID: 22329473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
